Ocugen grants OCU400 MENA rights in gene therapy licensing deal
On October 14, 2026, Ocugen granted Roots Pharmaceutical and Al-Dhow International Holding sole rights to commercialize its investigational OCU400 retinitis pigmentosa therapy in the Middle East and North Africa. The arrangement provides for initial payments of up to $4 million, sales-based milestones of up to $255 million and royalties of 22% on net sales, while Ocugen will make and deliver the therapy. Ocugen expects topline results from the Phase 3 liMeliGhT study in the first quarter of 2027.
Why it matters
The agreement gives Ocugen a regional commercialization partner and a potential stream of milestone and royalty income, subject to regulatory approval and product uptake. Ocugen retains responsibility for manufacturing and supply, while Roots provides the regional commercial infrastructure.
Key facts
- 1Ocugen announced the MENA licensing arrangement with Roots Pharmaceutical and Al-Dhow International Holding on October 14, 2026. stocktitan.net
- 2The contract provides for initial development payments of up to $4 million, sales milestones of up to $255 million and royalties of 22% of net sales. stocktitan.net
- 3Ocugen is responsible for manufacturing and supplying OCU400 under a related supply agreement. stocktitan.net
- 4Topline data from the Phase 3 liMeliGhT trial is expected in the first quarter of 2027. stocktitan.net
Open questions
- Materials 4 and 5 report different OCGN pre-market moves, at 2.53% and 2.78%, respectively.
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.